# Deletions of LPL and NKX3.1 in Prostate Cancer Progression: Game Changers or By-Standers in Tumor Evolution

**Authors:** Tereza Vodičková, Mária Wozniaková, Vladimír Židlík, Jana Žmolíková, Jana Dvořáčková, Adéla Kondé, Jana Schwarzerová, Michal Grepl, Jan Bouchal

PMC · DOI: 10.3390/biom15060758 · 2025-05-24

## TL;DR

This study explores whether LPL gene deletion in prostate cancer is a significant event or a by-stander to the loss of the tumor suppressor gene NKX3.1.

## Contribution

The study clarifies the biological relevance of LPL deletion in prostate cancer by distinguishing it from NKX3.1 loss.

## Key findings

- LPL protein expression was not significantly different between cancerous and benign prostate tissue.
- NKX3.1 loss occurred independently of LPL deletion in some cases, indicating LPL deletion is likely a passenger event.
- Deletion of the 8p21.3 region was associated with higher Gleason grade groups, suggesting clinical relevance.

## Abstract

The tumor suppressor gene NKX3.1 and the LPL gene are located in close proximity on chromosome 8, and their deletion has been reported in multiple studies. However, the significance of LPL loss may be misinterpreted due to its co-deletion with NKX3.1, a well-established event in prostate carcinogenesis. This study investigates whether LPL deletion represents a biologically relevant event or occurs merely as a bystander to NKX3.1 loss. We analyzed 28 formalin-fixed paraffin-embedded prostate cancer samples with confirmed LPL deletion and 28 without. Immunohistochemical staining was performed, and previously published whole-genome sequencing data from 103 prostate cancer patients were reanalyzed. Deletion of the 8p21.3 region was associated with higher Gleason grade groups. While NKX3.1 expression was significantly reduced in prostate cancer compared to benign prostatic hyperplasia, LPL protein expression showed no significant difference between cancerous and benign tissue, nor was it affected by the 8p21.3 deletion status. Copy number analysis confirmed the co-deletion of NKX3.1 and LPL in 54 patients. Notably, NKX3.1 loss without accompanying LPL deletion was observed in eight additional cases. These findings suggest that LPL deletion is a passenger event secondary to NKX3.1 loss and underscore the importance of cautious interpretation of cytogenetic findings involving the LPL locus.

## Linked entities

- **Genes:** LPL (lipoprotein lipase) [NCBI Gene 4023], NKX3-1 (NK3 homeobox 1) [NCBI Gene 4824]
- **Diseases:** prostate cancer (MONDO:0005159), benign prostatic hyperplasia (MONDO:0010811)

## Full-text entities

- **Genes:** LPL (lipoprotein lipase) [NCBI Gene 4023] {aka HDLCQ11, LIPD}, NKX3-1 (NK3 homeobox 1) [NCBI Gene 4824] {aka BAPX2, NKX3, NKX3.1, NKX3A}
- **Diseases:** benign prostatic hyperplasia (MESH:D011470), Tumor (MESH:D009369), Prostate Cancer (MESH:D011471), prostate carcinogenesis (MESH:D011472)
- **Chemicals:** paraffin (MESH:D010232), formalin (MESH:D005557)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12190382/full.md

---
Source: https://tomesphere.com/paper/PMC12190382